Moderna, Inc.

( )
MRNA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. 0.83%745.682.6%$767.75m
AMGNAmgen, Inc. 0.34%233.821.4%$621.98m
MRNAModerna, Inc. -0.04%125.620.0%$612.25m
BIIBBiogen, Inc. -2.15%261.691.8%$573.08m
GILDGilead Sciences, Inc. 0.21%65.451.0%$559.47m
VRTXVertex Pharmaceuticals, Inc. 0.46%302.021.9%$432.92m
ILMNIllumina, Inc. 6.56%218.523.2%$428.55m
SNSSSunesis Pharmaceuticals, Inc. -1.21%4.080.7%$285.21m
SAVACassava Sciences, Inc. -1.80%40.970.0%$181.06m
BNTXBioNTech SE -0.28%137.190.0%$112.04m
TECHBio-Techne Corp. 0.00%308.554.5%$100.54m
BMRNBioMarin Pharmaceutical, Inc. 1.84%89.534.2%$90.99m
NVAXNovavax, Inc. -3.61%18.7075.6%$84.10m
PRTAProthena Corp. Plc 1.15%58.1113.8%$78.29m
CRSPCRISPR Therapeutics AG -1.58%64.630.6%$77.63m

Company Profile

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.